Safety Profile of Levetiracetam
Abstract
Summary: Levetiracetam was approved in November 1999 as add‐on therapy for the treatment of partial‐onset seizures in adults (age 16 years and older). This review focuses on recently published data from four well‐controlled studies in patients with partial‐onset seizures with or without secondary generalization. When levetiracetam was given along with other antiepileptic drugs (AEDs), the most frequently reported adverse events were central nervous system related. Adverse events were usually mild to moderate in intensity, with the most frequently reported events occurring predominantly during the first 4 weeks of treatment. No relationship was apparent between the dose of levetiracetam and the most commonly reported adverse events in well‐controlled clinical trials within the recommended dose range of 1,000–3,000 mg/day. Levetiracetam is a Pregnancy Category C drug. Overall, when used in combination with other AEDs, levetiracetam was generally well tolerated as add‐on treatment for partial‐onset seizures.Keywords
This publication has 5 references indexed in Scilit:
- Long-term continuation of levetiracetam in patients with refractory epilepsyNeurology, 2001
- Efficacy and Tolerability of Levetiracetam 3000 mg/d in Patients with Refractory Partial Seizures: A Multicenter, Double‐Blind, Responder‐Selected Study Evaluating MonotherapyEpilepsia, 2000
- Multicenter Double‐Blind, Randomized, Placebo‐Controlled Trial of Levetiracetam as Add‐On Therapy in Patients with Refractory Partial SeizuresEpilepsia, 2000
- Levetiracetam for partial seizuresNeurology, 2000
- A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsySeizure: European Journal of Epilepsy, 2000